Lupin Obtains European Commission Approval for Biosimilar Ranibizumab

Lupin has received European Commission approval for its biosimilar ranibizumab, RanluspecTM, following a positive opinion from the Committee for Medicinal Products for Human Use. Ranibizumab treats several eye conditions including wet age-related macular degeneration and diabetic macular edema. The biosimilar will be commercialized by Sandoz across the EU, excluding Germany, and by both Sandoz and Biogaran in France. Lupin highlighted this as a testament to its scientific and manufacturing capabilities.